Literature DB >> 26098966

Donor characteristics and risk of hepatocellular carcinoma recurrence after liver transplantation.

L A Orci1,2, T Berney1,2, P E Majno1,2, S Lacotte1, G Oldani1,2, P Morel1,2, G Mentha1,2, C Toso1,2.   

Abstract

BACKGROUND: To date, studies assessing the risk of post-transplant hepatocellular carcinoma (HCC) recurrence have focused on tumour characteristics. This study investigated the impact of donor characteristics and graft quality on post-transplant HCC recurrence.
METHODS: Using the Scientific Registry of Transplant Recipients patients with HCC who received a liver transplant between 2004 and 2011 were included, and post-transplant HCC recurrence was assessed. A multivariable competing risk regression model was fitted, adjusting for confounders such as recipient sex, age, tumour volume, α-fetoprotein, time on the waiting list and transplant centre.
RESULTS: A total of 9724 liver transplant recipients were included. Patients receiving a graft procured from a donor older than 60 years (adjusted hazard ratio (HR) 1.38, 95 per cent c.i. 1.10 to 1.73; P = 0.006), a donor with a history of diabetes (adjusted HR 1.43, 1.11 to 1.83; P = 0.006) and a donor with a body mass index of 35 kg/m(2) or more (adjusted HR 1.36, 1.04 to 1.77; P = 0.023) had an increased rate of post-transplant HCC recurrence. In 3007 patients with documented steatosis, severe graft steatosis (more than 60 per cent) was also linked to an increased risk of recurrence (adjusted HR 1.65, 1.03 to 2.64; P = 0.037). Recipients of organs from donation after cardiac death donors with prolonged warm ischaemia had higher recurrence rates (adjusted HR 4.26, 1.20 to 15.1; P = 0.025).
CONCLUSION: Donor-related factors such as donor age, body mass index, diabetes and steatosis are associated with an increased rate of HCC recurrence after liver transplantation.
© 2015 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2015        PMID: 26098966     DOI: 10.1002/bjs.9868

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  11 in total

1.  The MTHFR polymorphism affect the susceptibility of HCC and the prognosis of HCC liver transplantation.

Authors:  C Wang; H Xie; D Lu; Q Ling; P Jin; H Li; R Zhuang; X Xu; S Zheng
Journal:  Clin Transl Oncol       Date:  2017-11-28       Impact factor: 3.405

Review 2.  One Shoot, Two Birds: Alleviating Inflammation Caused by Ischemia/Reperfusion Injury to Reduce the Recurrence of Hepatocellular Carcinoma.

Authors:  Hao Chen; Di Lu; Xinyu Yang; Zhihang Hu; Chiyu He; Huigang Li; Zuyuan Lin; Modan Yang; Xiao Xu
Journal:  Front Immunol       Date:  2022-05-11       Impact factor: 8.786

Review 3.  Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches.

Authors:  Gonzalo Sapisochin; Jordi Bruix
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-01-05       Impact factor: 46.802

Review 4.  Recent advances in liver transplantation for cancer: The future of transplant oncology.

Authors:  Phillipe Abreu; Andre Gorgen; Graziano Oldani; Taizo Hibi; Gonzalo Sapisochin
Journal:  JHEP Rep       Date:  2019-07-30

5.  Impact of donor age on liver transplant outcomes in patients with hepatocellular carcinoma: analysis of the SRTR database.

Authors:  Jie Zhou; Zhichao Huang; Zheng Chen; Fangshen Xu; Rongliang Tong; Shusen Zheng
Journal:  BMC Gastroenterol       Date:  2021-04-30       Impact factor: 3.067

Review 6.  An Update on Usage of High-Risk Donors in Liver Transplantation.

Authors:  Haris Muhammad; Duha Zaffar; Aniqa Tehreem; Peng-Sheng Ting; Cem Simsek; Ilker Turan; Saleh Alqahtani; Behnam Saberi; Ahmet Gurakar
Journal:  J Clin Med       Date:  2021-12-31       Impact factor: 4.241

Review 7.  Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models.

Authors:  Wojciech Andrzej Straś; Dariusz Wasiak; Beata Łągiewska; Olga Tronina; Marta Hreńczuk; Joanna Gotlib; Wojciech Lisik; Piotr Małkowski
Journal:  Ann Transplant       Date:  2022-01-26       Impact factor: 1.530

8.  Liver transplantation for hepatocellular carcinoma using grafts from uncontrolled circulatory death donation.

Authors:  Anisa Nutu; Iago Justo; Alberto Marcacuzco; Óscar Caso; Alejandro Manrique; Jorge Calvo; Álvaro García-Sesma; María García-Conde; María Santos Gallego; Carlos Jiménez-Romero
Journal:  Sci Rep       Date:  2021-06-29       Impact factor: 4.379

9.  Ischemia-reperfusion injury and the risk of hepatocellular carcinoma recurrence after deceased donor liver transplantation.

Authors:  Michał Grąt; Marek Krawczyk; Karolina M Wronka; Jan Stypułkowski; Zbigniew Lewandowski; Michał Wasilewicz; Piotr Krawczyk; Karolina Grąt; Waldemar Patkowski; Krzysztof Zieniewicz
Journal:  Sci Rep       Date:  2018-06-12       Impact factor: 4.379

10.  Ischemia reperfusion injury promotes recurrence of hepatocellular carcinoma in fatty liver via ALOX12-12HETE-GPR31 signaling axis.

Authors:  Faji Yang; Yuheng Zhang; Haozhen Ren; Jinglin Wang; Longcheng Shang; Yang Liu; Wei Zhu; Xiaolei Shi
Journal:  J Exp Clin Cancer Res       Date:  2019-12-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.